

Scandinavian Real Heart AB Corrects Weekday in Notice of Extraordinary General Meeting

Scandinavian Real Heart AB (publ) wishes to inform stakeholders of a correction in the notice published on 24 October 2025 regarding the Extraordinary General Meeting.

The notice incorrectly stated that the meeting would be held on Tuesday, 24 November 2025. The correct information is: Monday, 24 November 2025.

Please note that the date – 24 November 2025 – remains correct; only the weekday has been adjusted. The time and venue of the meeting are unchanged.

We regret the error and apologise for any confusion this may have caused. For further details, please refer to the updated notice on our website or contact the company directly.

For more information, please contact:

Ina Laura Perkins, CEO

Phone: +46 (0) 70 406 49 21

E-mail: inalaura.perkins@realheart.se

Certified Adviser: Svensk Kapitalmarknadsgranskning AB, www.skmg.se

About Us

Scandinavian Real Heart AB (publ) is developing the first artificial heart that mimics the shape, function, and blood flow pattern of the human heart. These unique product features provide completely new opportunities to save lives and give patients a good quality of life while waiting for a heart transplant. In the future, artificial hearts may also become an alternative to transplantation for broader groups of patients with severe heart failure. Realheart® TAH (Total Artificial Heart) is now being evaluated in extensive preclinical trials ahead of a first clinical study in patients. The company's shares are traded on Nasdaq Stockholm First North Growth Market. For more information, visit www.realheart.se